About the Commission on Cancer. ACS. https://www.facs.org/quality-programs/cancer-programs/commission-on-cancer/about/. Accessed 4 May 2024.

About the National Cancer Database. ACS. https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/about/. Accessed 28 April 2024.

Miller ME, Bleicher RJ, Kaufman CS, et al. Impact of breast center accreditation on compliance with breast quality performance measures at Commission on Cancer-accredited centers. Ann Surg Oncol. 2019;26(5):1202–11. https://doi.org/10.1245/s10434-018-07108-7.

Article  PubMed  Google Scholar 

Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–9. https://doi.org/10.1001/jamaoncol.2015.4508.

Article  PubMed  PubMed Central  Google Scholar 

Cone EB, Marchese M, Paciotti M, et al. Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open. 2020;3(12):e2030072. https://doi.org/10.1001/jamanetworkopen.2020.30072.

Article  PubMed  PubMed Central  Google Scholar 

Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012–2014. Ann Surg Oncol. 2019;26(6):1604–12. https://doi.org/10.1245/s10434-019-07213-1.

Article  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg Lond Engl. 2014;12(12):1495–9. https://doi.org/10.1016/j.ijsu.2014.07.013.

Article  Google Scholar 

Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779–85. https://doi.org/10.1097/SLA.0b013e318211cc0f.

Article  PubMed  Google Scholar 

Bleicher RJ, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012;30(36):4485–92. https://doi.org/10.1200/JCO.2012.41.7972.

Article  PubMed  PubMed Central  Google Scholar 

Verdone CG, Bayron JA, Chang C, et al. A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA. Breast Cancer Res Treat. 2022;191(3):513–22. https://doi.org/10.1007/s10549-021-06460-9.

Article  PubMed  PubMed Central  Google Scholar 

Punglia RS, Saito AM, Neville BA, Earle CC, Weeks JC. Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. BMJ. 2010;340:c845. https://doi.org/10.1136/bmj.c845.

Article  PubMed  PubMed Central  Google Scholar 

Lenti MV, Sottotetti F, Corazza GR. Tackling the clinical complexity of breast cancer. Drugs Context. 2022;11:1–5. https://doi.org/10.7573/dic.2022-2-3.

Article  Google Scholar 

Waks AG, King TA, Winer EP. Timeliness in breast cancer treatment-the sooner, the better. JAMA Oncol. 2016;2(3):302–4. https://doi.org/10.1001/jamaoncol.2015.4506.

Article  PubMed  Google Scholar 

Bleicher RJ, Chang C, Wang CE, et al. Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Res Treat. 2019;173(3):603–17. https://doi.org/10.1007/s10549-018-5046-x.

Article  PubMed  Google Scholar 

Olivotto IA, Lesperance ML, Truong PT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol. 2009;27(1):16–23. https://doi.org/10.1200/JCO.2008.18.1891.

Article  PubMed  Google Scholar 

Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65(5):1353–60. https://doi.org/10.1016/j.ijrobp.2006.03.048di.

Article  PubMed  Google Scholar 

Zheleva V, Nelson RA, Dumitra S, Vora NL, Lai LL. Time to adjuvant radiotherapy in breast cancer affects survival: implications for the American College of Surgeons Commission on Cancer quality metrics. Ann Surg Oncol. 2020;27(8):2614–25. https://doi.org/10.1245/s10434-020-08326-8.

Article  PubMed  Google Scholar 

Bleicher RJ, Moran MS, Ruth K, et al. The impact of radiotherapy delay in breast conservation patients not receiving chemotherapy and the rationale for dichotomizing the radiation oncology time-dependent standard into two quality measures. Ann Surg Oncol. 2022;29(1):469–81. https://doi.org/10.1245/s10434-021-10512-1.

Article  PubMed  Google Scholar 

Vujovic O, Yu E, Cherian A, Dar AR, Stitt L, Perera F. Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(3):760–4. https://doi.org/10.1016/j.ijrobp.2005.08.004.

Article  PubMed  Google Scholar 

Fasola CE, Sharp HJ, Clavin NW, et al. Effect of delayed oncoplastic reduction mammoplasty on radiation treatment delay following breast-conserving surgery for breast cancer. Ann Surg Oncol. 2023;30(13):8362–70. https://doi.org/10.1245/s10434-023-14177-w.

Article  PubMed  Google Scholar 

Elder EE, Brandberg Y, Björklund T, et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast Edinb Scotl. 2005;14(3):201–8. https://doi.org/10.1016/j.breast.2004.10.008.

Article  Google Scholar 

Nano MT, Gill PG, Kollias J, Bochner MA, Malycha P, Winefield HR. Psychological impact and cosmetic outcome of surgical breast cancer strategies. ANZ J Surg. 2005;75(11):940–7. https://doi.org/10.1111/j.1445-2197.2005.03517.x.

Article  PubMed  Google Scholar 

Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267–74. https://doi.org/10.1007/s10549-018-5018-1.

Article  PubMed  Google Scholar 

Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat. 2020;184(1):249–54. https://doi.org/10.1007/s10549-020-05828-7.

Article  PubMed  PubMed Central  Google Scholar 

Livingston-Rosanoff D, Hanlon B, Marka N, et al. Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: a study of US breast cancer patients. Breast J. 2020;26(4):625–9. https://doi.org/10.1111/tbj.13625.

Article  PubMed  Google Scholar 

deGagliato MeloLei DX, Giordano SH, et al. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast cancer. The Oncologist. 2020;25(9):749–57. https://doi.org/10.1634/theoncologist.2019-0744.

Article  Google Scholar 

Prakash I, Thomas SM, Greenup RA, et al. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. Breast Cancer Res Treat. 2021;186(2):535–50. https://doi.org/10.1007/s10549-020-06012-7.

Article  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.

Article  Google Scholar 

Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59. https://doi.org/10.1056/NEJMoa1612645.

Article  PubMed  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. https://doi.org/10.1056/NEJMoa1814017.

Article  Google Scholar 

Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544–52. https://doi.org/10.1002/cncr.29348.

Article  PubMed  Google Scholar 

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8. https://doi.org/10.1245/s10434-018-6531-5.

Article  PubMed  Google Scholar 

Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA J Am Med Assoc. 2009;302(14):1551–6. https://doi.org/10.1001/jama.2009.1450.